Davey S. Scoon

Board of Trustees, Allianz Global Investors

Davey Scoon’s business career has included senior executive positions in finance and administration at Tom’s of Maine, Inc., Sunlife Financial U.S. and Liberty Funds Group of Boston (formerly Colonial Management), as well as serving as a CPA with Price Waterhouse & Company. He is currently chairman of the Board of Trustees for Allianz Global Investors and a director and chairman of the Audit Committee of AMAG Pharmaceuticals, Inc. Among other roles, he previously served as non-executive chairman of Tufts Health Plan. Davey is also an adjunct professor teaching accounting at the University of Wisconsin-Madison. He earned an MBA from Harvard Business School and a BBA in Business Administration from the University of Wisconsin.

Team members

David Chiswell, Ph.D.

Chairman of the Board, Albireo; Former Chief Executive Officer, Kymab; Non-Executive Chairman, IGEM Therapeutics; Board Member of Bond 2 Development 2 GP

Anne Klibanski, M.D.

Laurie Carrol Guthart Professor of Medicine, Harvard Medical School; President and CEO, Partners HealthCare

Michael Gutch, Ph.D.

Chief Business Officer and Chief Financial Officer, Entasis Therapeutics

Roger A. Jeffs, Ph.D.

Former President and co-CEO, United Therapeutics (retired)

Stephanie S. Okey, M.S.

Former Senior Vice President, Head of North America, Rare Diseases, Genzyme, a Sanofi Company

Davey S. Scoon

Board of Trustees, Allianz Global Investors

Ron Cooper

President and Chief Executive Officer